Follicular Lymphoma
From the Journals
Rituximab biosimilar looks equivalent in follicular lymphoma
CT-P10 has been recommended for approval in the U.S. by the FDA’s Oncologic Drugs Advisory Committee.
News
R-CHOP effective as first-line treatment in FL
Long-term data suggest R-CHOP can be effective as first-line treatment for patients with follicular lymphoma (FL). In a phase 2-3 trial,...
From the Journals
R-CHOP looks viable as first line in follicular lymphoma
Long-term follow-up of a randomized trial showed durable efficacy of R-CHOP with no increase in histological transformation or secondary cancers...
News
Combo appears safe, active in rel/ref NHL
The combination of Hu5F9-G4 (5F9) and rituximab was considered safe and produced durable complete responses (CRs) in patients with relapsed or...
News
Sandoz won’t seek U.S. approval for rituximab biosimilar
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimiliar of Rituxan/Mabthera. GP2013 (Rixathon,...
News
Sandoz halts pursuit of U.S. approval for rituximab biosimilar
From the Journals
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphoma
Mainly low-grade toxic effects were seen on treatment with Hu5F9-G4 and rituximab in the study of relapsed and refractory patients.
From the Journals
Older age predicts mortality after alloHCT in NHL, but not relapse
The researchers said older age was an independent risk factor for nonrelapse mortality.
From the Journals
Entospletinib falls short in relapsed/refractory DLBCL
The oral, selective inhibitor of spleen tyrosine kinase had a high rate of adverse events and treatment interruption in the phase 2 study.
News
Inhibitor receives orphan designation for PTCL
The U.S.
From the Journals
Frontline rituximab shows long-term success in indolent lymphoma
A study with 10-year follow-up data suggests that chemotherapy can be delayed in symptomatic indolent lymphoma patients.